Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Operating Leases: 2014-2025

Historic Operating Leases for Lineage Cell Therapeutics (LCTX) over the last 11 years, with Sep 2025 value amounting to $1.5 million.

  • Lineage Cell Therapeutics' Operating Leases fell 1.17% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 1.17%. This contributed to the annual value of $1.3 million for FY2024, which is 34.56% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Operating Leases stood at $1.5 million for Q3 2025, which was up 43.19% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Operating Leases ranged from a high of $2.9 million in Q4 2022 and a low of $1.0 million during Q1 2025.
  • Moreover, its 3-year median value for Operating Leases was $1.8 million (2024), whereas its average is $1.7 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Operating Leases surged by 47.35% in 2022, and later tumbled by 51.16% in 2025.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Operating Leases stood at $1.9 million in 2021, then surged by 47.35% to $2.9 million in 2022, then crashed by 30.80% to $2.0 million in 2023, then tumbled by 34.56% to $1.3 million in 2024, then dropped by 1.17% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.1 million for Q2 2025, and $1.0 million during Q1 2025.